Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus
20 Octubre 2009 - 9:54AM
PR Newswire (US)
SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc.
(OTC Bulletin Board: AEMD) announced today that research studies
have documented the Aethlon Hemopurifier® is effective in capturing
the current pandemic strain of the H1N1 Swine Flu Virus. The
Hemopurifier® is the first-in-class medical device able to
selectively remove infectious viruses and immunosuppressive
proteins from the bloodstream. During invitro studies, the
Hemopurifier® removed 68% of H1N1 virus from blood plasma in 30
minutes, 80% of the virus in two hours, and a 96% reduction of H1N1
was observed at six hours. The studies were performed by third
party researchers approved by the United States Department of
Health and Human Services (HHS) to house and conduct research on
the current pandemic strains of H1N1 virus. (Logo:
http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b) "The
confirmation of the same Hemopurifier® we are advancing in
Hepatitis-C (HCV) care, having significant activity against H1N1
virus is quite timely when considering the evolving rate of the
pandemic," stated Aethlon Chairman & CEO, Jim Joyce. At
present, the 2009 H1N1 influenza virus is the predominant influenza
virus in circulation in most countries worldwide. Additional
information on the virus, including situational updates can be
accessed online at http://www.cdc.gov/H1N1flu. Previous studies of
the Hemopurifier® also demonstrated the ability of the device to
capture both the reconstructed Spanish flu of 1918 virus (1918rv)
and the H5N1 avian influenza virus (Bird Flu). As an adjunct
therapy, the Hemopurifier® offers to improve the benefit of
antiviral drugs against highly virulent strains of influenza and
provides a therapeutic option against emerging strains of influenza
that are resistant to drug and vaccine therapies. About Aethlon
Medical Aethlon Medical creates diagnostic and therapeutic device
solutions for infectious disease and cancer. Our Hemopurifier®
represents the first-in-class medical device to selectively adsorb
viruses and immunosuppressive toxins from the bloodstream. The
Hemopurifier® seeks to improve Hepatitis-C treatment outcomes and
serves as a broad-spectrum treatment countermeasure against
bioterror and pandemic threats. Additional information regarding
Aethlon Medical can be accessed online at
http://www.aethlonmedical.com/. Certain of the statements herein
may be forward-looking and involve risks and uncertainties. Such
forward-looking statements involve assumptions, known and unknown
risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Aethlon Medical, Inc. to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such potential risks and uncertainties include, without
limitation, the capability of the Hemopurifier® to reduce viral
loads and other disease conditions, including H1N1 influenza, the
Company's ability to raise capital when needed, the Company's
ability to complete the development of its planned products, the
ability of the Company to obtain FDA and other regulatory approvals
permitting the sale of its products, the Company's ability to
manufacture its products and provide its services, the impact of
government regulations, patent protection on the Company's
proprietary technology, product liability exposure, uncertainty of
market acceptance, competition, technological change, and other
risk factors. In such instances, actual results could differ
materially as a result of a variety of factors, including the risks
associated with the effect of changing economic conditions and
other risk factors detailed in the Company's Securities and
Exchange Commission filings. Contacts: RedChip Companies, Inc. Jon
Cunningham 1-800-733-2447, Ext. 107 Jim Joyce Chairman, CEO
858.459.7800 x301 Jim Frakes Senior VP Finance 858.459.7800 x300
http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b
http://photoarchive.ap.org/ DATASOURCE: Aethlon Medical, Inc.
CONTACT: Jon Cunningham of RedChip Companies, Inc., 1-800-733-2447,
Ext. 107, , for Aethlon Medical, Inc.; or Jim Joyce, Chairman, CEO,
+1-858-459-7800, Ext. 301, , or Jim Frakes, Senior VP Finance,
+1-858-459-7800, Ext. 300, , both of Aethlon Medical, Inc. Web
Site: http://www.aethlonmedical.com/
Copyright